Sequana Medical Increases Share Capital for Growth Initiatives
Sequana Medical NV (the "Company" or "Sequana Medical") is excited to announce recent developments concerning its share capital and outstanding shares. By enhancing its financial capabilities, Sequana Medical is reinforcing its position as a trailblazer in the treatment of fluid overload associated with liver diseases, heart failure, and cancer.
In a significant move, as part of a strategic initiative involving a contribution in kind of a EUR 400,000.00 commitment fee, the Company's share capital experienced an uplift. Following the completion of this in-kind contribution on a notable date, the share capital has risen from EUR 5,430,706.55 to EUR 5,477,375.45. Concurrently, the total number of issued shares has increased, now reaching 52,867,073 ordinary shares. This increment was made possible through a total issuance of 450,472 new shares at an approximate issue price per share of EUR 0.888, aimed at benefiting GEM Global Yield LLC SCS ("GEM").
Overview of Recent Changes
The decisions regarding this capital increase were made by the Company's board of directors during a recent meeting held prior to the formal documentation at a notary public. Furthermore, the board has tentatively approved an additional capital increase in cash involving multiple subscription requests from the Company. The planned cash increase could result in issuing up to 23,070,491 new shares, with a potential financial target amounting to EUR 2,390,102.91, provided that it remains within the authorized capital provision. Importantly, any capital raised will remain under the initial maximum commitment of EUR 20,000,000.00.
Subscription Rights and Potential Share Issuance
Currently, the share options in circulation total 3,899,576. If these rights are exercised, they will facilitate the subscription of 5,066,304 new shares that carry voting rights. The distribution of these shares as per the exercise of specific share option plans is noteworthy:
- Under the 'Executive Share Options', there can be up to 261,895 new shares issued, based on the exercise of 90,780 remaining options;
- The '2018 Share Options' could lead to 687,784 new shares being issued, with an option issuance for directors and employees;
- Under the '2021 Share Options', an equal potential exists for the issuance of 188,370 new shares;
- The '2023 Share Options' can see up to 1,000,000 new shares being issued;
- Bootstrap Europe S.C.SP. may receive 302,804 new shares under specific warrant conditions;
- Kreos Capital VII Aggregator SCSp. is poised for up to 1,567,819 new shares through its outstanding warrants;
- Additionally, 1,057,632 new shares may also be made available through 2023 Investor Warrants.
Commitment to Innovative Solutions
Sequana Medical stands at the forefront of developing groundbreaking treatment options for patients facing fluid overload complications. The challenges faced by patients with liver diseases, heart failure, and cancer remain significant, often leading to increased hospital visits and adverse effects on life quality. Recognizing this, Sequana Medical aims to provide innovative and effective solutions to alleviate these medical concerns.
With proprietary solutions like the alfapump® and DSR®, Sequana Medical is focused on enhancing the lives of patients who struggle with the limitations of standard care treatments like diuretics. These innovative platforms are designed not only to manage severe fluid overload issues but also to potentially reduce healthcare costs while improving patient care outcomes.
Regulatory Approvals
Furthermore, Sequana Medical has reached significant regulatory milestones. Having gained US FDA approval for the alfapump System aimed at treating recurrent or refractory ascites due to liver cirrhosis, the Company is planning to initiate commercialization efforts in the US. This launch is strategically timed to coincide with the operational activities of the predominant liver transplant centers.
By fostering innovation and addressing unmet medical needs, Sequana Medical is making strides toward becoming a leader in its domain. The recent share capital increase represents a vital step in securing the necessary resources to propel the Company into its next phase of growth and development.
Frequently Asked Questions
What does the recent capital increase mean for Sequana Medical?
The capital increase strengthens Sequana Medical's financial foundation, enabling further investments in developing innovative treatments for fluid overload conditions.
How many outstanding shares does Sequana Medical currently have?
Sequana Medical currently has 52,867,073 outstanding ordinary shares following the recent issuance.
What are the new proprietary treatment options launched by Sequana Medical?
Sequana Medical has developed the alfapump® and DSR® systems to address challenging fluid overload conditions in patients.
When does Sequana Medical plan to start US commercialization?
The Company is targeting a mid-Q3 timeframe for initiating US commercialization of its alfapump system.
What is the significance of the board meeting concerning share capital?
The board meeting was crucial as it authorized the increase in share capital, indicating a step forward in the Company’s financial strategy and growth trajectory.
